Literature DB >> 24990698

Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.

Guan Jiang1, Ai-Jun Jiang, Yong Xin, Lian-Tao Li, Qian Cheng, Jun-Nian Zheng.   

Abstract

Temozolomide (TMZ) is an alkylating agent that is widely used in chemotherapy for cancer. A key mechanism of resistance to TMZ is the overexpression of O(6)-methylguanine-DNA methyltransferase (MGMT). MGMT specifically repairs the DNA O(6)-methylation damage induced by TMZ and irreversibly inactivates TMZ. Regulation of MGMT expression and research regarding the mechanism of TMZ resistance will help rationalize the clinical use of TMZ. In this review, we provide an overview of recent advances in the field, with particular emphasis on MGMT structure, function, expression regulation, and the association between MGMT and resistance to TMZ.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24990698     DOI： 10.1007/s11033-014-3549-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN： 0301-4851            Impact factor:   2.316


  65 in total

1.  Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.

Authors:  Michael S Bobola; Douglas D Kolstoe; A Blank; John R Silber
Journal:  Mol Cancer Ther       Date:  2010-05       Impact factor: 6.261

2.  Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in Tunisian patients.

Authors:  S Challouf; S Ziadi; R Zaghdoudi; F Ksiaa; R Ben Gacem; M Trimeche
Journal:  Clin Chim Acta       Date:  2012-01-24       Impact factor: 3.786

3.  Research on DNA methylation of human osteosarcoma cell MGMT and its relationship with cell resistance to alkylating agents.

Authors:  Jun Guo; Qiu Cui; WeiHao Jiang; Cheng Liu; DingFeng Li; Yanjun Zeng
Journal:  Biochem Cell Biol       Date:  2013-01-25       Impact factor: 3.626

Review 4.  A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.

Authors:  Guan Jiang; Zhi-Ping Wei; Dong-Sheng Pei; Yong Xin; Yan-Qun Liu; Jun-Nian Zheng
Journal:  Biochem Biophys Res Commun       Date:  2011-02-15       Impact factor: 3.575

5.  Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Authors:  H S Friedman; J Pluda; J A Quinn; R B Ewesuedo; L Long; A H Friedman; I Cokgor; O M Colvin; M M Haglund; D M Ashley; J N Rich; J Sampson; A E Pegg; R C Moschel; R E McLendon; J M Provenzale; E S Stewart; S Tourt-Uhlig; A M Garcia-Turner; J E Herndon; D D Bigner; M E Dolan
Journal:  J Clin Oncol       Date:  2000-10-15       Impact factor: 44.544

Review 6.  Repair of O(6)-alkylguanine by alkyltransferases.

Authors:  A E Pegg
Journal:  Mutat Res       Date:  2000-04       Impact factor: 2.433

7.  IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression.

Authors:  Shannon F Rosati; Regan F Williams; Lindsey C Nunnally; Mackenzie C McGee; Thomas L Sims; Lorraine Tracey; Junfang Zhou; Meiyun Fan; Catherine Y Ng; Amit C Nathwani; Clinton F Stewart; Lawrence M Pfeffer; Andrew M Davidoff
Journal:  Mol Cancer Ther       Date:  2008-12-03       Impact factor: 6.261

8.  Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus.

Authors:  Doerthe Kuester; Wa'el El-Rifai; DunFa Peng; Petra Ruemmele; Ivonne Kroeckel; Brigitte Peters; Christopher A Moskaluk; Manfred Stolte; Klaus Mönkemüller; Frank Meyer; Hans-Ulrich Schulz; Arndt Hartmann; Albert Roessner; Regine Schneider-Stock
Journal:  Cancer Lett       Date:  2008-11-21       Impact factor: 8.679

9.  Advances in the management of glioblastoma: the role of temozolomide and MGMT testing.

Authors:  Reena P Thomas; Lawrence Recht; Seema Nagpal
Journal:  Clin Pharmacol       Date:  2012-12-27

10.  Immunohistochemical assessment of MGMT expression and p53 mutation in glioblastoma multiforme.

Authors:  Marziyeh Lotfi; Sima Afsharnezhad; Hamid Reza Raziee; Kamran Ghaffarzadegan; Samaneh Sharif; Jamal Shamsara; Sara Lary; Javad Behravan
Journal:  Tumori       Date:  2011 Jan-Feb
View more
  7 in total

1.  Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.

Authors:  Nathan B Roberts; Aymen Alqazzaz; Jacqueline R Hwang; Xiulan Qi; Achsah D Keegan; Anthony J Kim; Jeffrey A Winkles; Graeme F Woodworth
Journal:  J Neurooncol       Date:  2018-08-21       Impact factor: 4.130

2.  Ursolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expression.

Authors:  Zhongling Zhu; Shuangshuang Du; Fengxia Ding; Shanshan Guo; Guoguang Ying; Zhao Yan
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

3.  Glioblastoma Recurrence Correlates With Increased APE1 and Polarization Toward an Immuno-Suppressive Microenvironment.

Authors:  Amanda L Hudson; Nicole R Parker; Peter Khong; Jonathon F Parkinson; Trisha Dwight; Rowan J Ikin; Ying Zhu; Jason Chen; Helen R Wheeler; Viive M Howell
Journal:  Front Oncol       Date:  2018-08-13       Impact factor: 6.244

4.  Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity.

Authors:  Dong Woo Kang; Won Chan Hwang; Yu Na Noh; Kang Seo Park; Do Sik Min
Journal:  J Pathol       Date:  2020-09-10       Impact factor: 7.996

5.  Radiation enhances the delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts.

Authors:  Prakash Ambady; Yingjen Jeffrey Wu; Cymon N Kersch; Joshua M Walker; Samantha Holland; Leslie L Muldoon; Edward A Neuwelt
Journal:  Cancer Gene Ther       Date:  2021-04-14       Impact factor: 5.854

6.  mTOR regulates the expression of DNA damage response enzymes in long-lived Snell dwarf, GHRKO, and PAPPA-KO mice.

Authors:  Graham Dominick; Jacqueline Bowman; Xinna Li; Richard A Miller; Gonzalo G Garcia
Journal:  Aging Cell       Date:  2016-09-13       Impact factor: 9.304

Review 7.  Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies.

Authors:  Malak Abedalthagafi
Journal:  Oncotarget       Date:  2018-10-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.